Life sciences strategy author wants UK to follow US example and issues Brexit warning

30 August 2017

The life sciences did not feature prominently in mainstream debates on membership of the European Union (EU), but the UK government is going the right way about ensuring that the sector thrives as the country prepares to leave the trade bloc, according to industry’s response to new proposals.

On Wednesday the government published the Life Sciences Industrial Strategy to help the sector become an international benchmark for success.

The strategy follows a comprehensive cross-sector review into the long-term future of the industry by the prominent immunologist and geneticist Sir John Bell. It brings together input and recommendations from pharma giants such as AstraZeneca (LSE: AZN), GlaxoSmithKline (LSE: GSK), Johnson & Johnson (NYSE: JNJ) and Merck & Co (NYSE: MRK), as well healthcare groups, small and medium-sized enterprises and charities.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK